Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure

被引:116
作者
Cohen-Solal, Alain [1 ,2 ]
Logeart, Damien [2 ]
Huang, Bidan [3 ]
Cai, Danlin [3 ]
Nieminen, Markku S. [4 ]
Mebazaa, Alexandre [2 ]
机构
[1] Univ Paris 07, Hop Lariboisiere, AP HP, INSERM,Dept Cardiol,U 942, F-75475 Paris 10, France
[2] Fac Med Denis Diderot, INSERM, U 942, Paris, France
[3] Abbott Labs, Abbott Pk, IL 60064 USA
[4] Univ Cent Hosp, Helsinki, Finland
关键词
B-type natriuretic peptide; prognosis; acute decompensation of heart failure; levosimendan; dobutamine; ACUTE DYSPNEA; MANAGEMENT; BNP; ECHOCARDIOGRAPHY; PRESSURES; DIAGNOSIS; PROBNP; ASSAY;
D O I
10.1016/j.jacc.2009.02.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this analysis was to examine whether decreases in B-type natriuretic peptide (BNP) levels during the first few days of hospitalization were associated with greater survival in patients with severe acutely decompensated heart failure (ADHF). Background BNP level is a prognostic marker for all-cause mortality (ACM) in ADHF; whether early BNP changes can also help predict outcome in patients who need inotropes for treatment of severe ADHF is not known. Methods We retrospectively assessed the association between changes in BNP levels and ACM in patients from the SURVIVE (Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support) trial-a randomized, controlled trial comparing levosimendan to dobutamine treatment in patients hospitalized with ADHF. BNP levels were measured at baseline and at days 1, 3, and 5. A patient was classified as a "responder" if the follow-up BNP level was >= 30% lower than baseline BNP. The relationship between early BNP response and subsequent ACM over short-(31-day) and long-term (180-day) intervals was evaluated. Results Of 1,327 SURVIVE patients, this analysis included 1,038 who had BNP samples at both baseline and day 5. Responders at days 1, 3, and 5 had lower ACM than did nonresponders (p <= 0.001), with day-5 levels showing superior discriminating value. Short-term ACM (31-day) risk reduction was 67% in day-5 BNP responders compared with nonresponders, whereas long-term (180-day) ACM risk reduction was 47%. Conclusions Patients with lowered BNP on treatment for ADHF had reduced mortality risks (31- and 180-day) compared to those with little or no BNP decrease. These results suggest that early lowering of BNP predicts both short- and long-term mortality risks. BNP reduction may therefore serve as a suitable prognostic marker of ACM. (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support [SURVIVE]; NCT00348504) (J Am Coll Cardiol 2009; 53: 2343-8) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:2343 / 2348
页数:6
相关论文
共 19 条
[1]   N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients [J].
Bettencourt, P ;
Azevedo, A ;
Pimenta, J ;
Frioes, F ;
Ferreira, S ;
Ferreira, A .
CIRCULATION, 2004, 110 (15) :2168-2174
[2]   Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure [J].
Braunschweig, Frieder ;
Fahrleitner-Pammer, Astrid ;
Mangiavacchi, Maurizio ;
Ghio, Stefano ;
Fotuhi, Parwis ;
Hoppe, Uta C. ;
Linde, Cecilia .
EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (08) :797-803
[3]   Natriureettic peptides [J].
Daniels, Lori B. ;
Maisel, Alan S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (25) :2357-2368
[4]   Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure [J].
Gackowski, A ;
Isnard, R ;
Golmard, JL ;
Pousset, F ;
Carayon, A ;
Montalescot, G ;
Hulot, JS ;
Thomas, D ;
Piwowarska, W ;
Komajda, M .
EUROPEAN HEART JOURNAL, 2004, 25 (20) :1788-1796
[5]   Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure -: The STARS-BNP multicenter study [J].
Jourdain, Patrick ;
Jondeau, Guillaume ;
Funck, Francois ;
Gueffet, Pascal ;
Le Helloco, Alain ;
Donal, Erwan ;
Aupetit, Jean F. ;
Aumont, Marie C. ;
Galinier, Michel ;
Eicher, Jean C. ;
Cohen-Solal, Alain ;
Juilliere, Yves .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (16) :1733-1739
[6]   A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study [J].
Kazanegra, R ;
Cheng, V ;
Garcia, A ;
Krishnaswamy, P ;
Gardetto, N ;
Clopton, P ;
Maisel, A .
JOURNAL OF CARDIAC FAILURE, 2001, 7 (01) :21-29
[7]   Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea [J].
Logeart, D ;
Saudubray, C ;
Beyne, P ;
Thabut, G ;
Ennezat, PV ;
Chavelas, C ;
Zanker, C ;
Bouvier, E ;
Solal, AC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (10) :1794-1800
[8]   Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure [J].
Logeart, D ;
Thabut, G ;
Jourdain, P ;
Chavelas, C ;
Beyne, P ;
Beauvais, F ;
Bouvier, E ;
Solal, AC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (04) :635-641
[9]   B-type natriuretic peptide (BNP) is more sensitive to rapid hemodynamic changes in acute heart failure than N-terminal proBNP [J].
Mair, Johannes ;
Falkensammer, Gerda ;
Poelzl, Gerhard ;
Hammerer-Lercher, Angelika ;
Griesmacher, Andrea ;
Pachinger, Otmar .
CLINICA CHIMICA ACTA, 2007, 379 (1-2) :163-166
[10]   Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure [J].
Maisel, AS ;
Krishnaswamy, P ;
Nowak, RM ;
McCord, J ;
Hollander, JE ;
Duc, P ;
Omland, T ;
Storrow, AB ;
Abraham, WT ;
Wu, AHB ;
Clopton, P ;
Steg, PG ;
Westheim, A ;
Knudsen, CW ;
Perez, A ;
Kazanegra, R ;
Herrmann, HC ;
McCullough, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (03) :161-167